- Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
- Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
- Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
- Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
- Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
- Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
- Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board
- Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow
- Akoya Biosciences Deploys the MaxFuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory at Stanford University for Multiomic Integration of Spatial and Single-cell Data on the Enable Medicine Platform
- Akoya Biosciences Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2023 and Provides 2024 Outlook
More ▼
Key statistics
On Friday, Akoya Biosciences Inc (AKYA:NSQ) closed at 4.04, 32.89% above the 52 week low of 3.04 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.02 |
---|---|
High | 4.23 |
Low | 3.92 |
Bid | 3.75 |
Offer | 4.55 |
Previous close | 3.99 |
Average volume | 94.32k |
---|---|
Shares outstanding | 49.34m |
Free float | 25.34m |
P/E (TTM) | -- |
Market cap | 199.34m USD |
EPS (TTM) | -1.48 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼